Binimetinib

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 457 publications

Giant scalp melanoma in an immunosuppressed patient.

Giant scalp melanoma in an immunosuppressed patient.

Journal: JAAD case reports

Published: August 16, 2026

Colorectal neuroendocrine neoplasm organoids reveal the potential therapeutic value of targeting BRAF mutations.

Colorectal neuroendocrine neoplasm organoids reveal the potential therapeutic value of targeting BRAF mutations.

Journal: Journal of the Endocrine Society

Published: June 17, 2026

A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study.

A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 17, 2026

Incidence and predictors of hemorrhage in pediatric low-grade glioma.

Incidence and predictors of hemorrhage in pediatric low-grade glioma.

Journal: Journal of neuro-oncology

Published: May 29, 2026

An integrated in silico and SPR-based workflow identifies FDA-approved drugs as previously unrecognized SIRT3 binders.

An integrated in silico and SPR-based workflow identifies FDA-approved drugs as previously unrecognized SIRT3 binders.

Journal: Bioorganic chemistry

Published: May 23, 2026

Tailored management of a melanoma patient with bleeding brain metastases and deep vein thrombosis with thrombectomy.

Tailored management of a melanoma patient with bleeding brain metastases and deep vein thrombosis with thrombectomy.

Journal: CNS oncology

Published: May 20, 2026

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 16, 2026

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.

Journal: Future oncology (London, England)

Published: March 31, 2026

A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.

A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.

Journal: Future oncology (London, England)

Published: March 30, 2026

A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary.

A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary.

Journal: Future oncology (London, England)

Published: March 24, 2026

Crystal structure of binimetinib (Form A), C17H15BrF2N4O3, from synchrotron X-ray powder diffraction data and density functional theory.

Crystal structure of binimetinib (Form A), C17H15BrF2N4O3, from synchrotron X-ray powder diffraction data and density functional theory.

Journal: Acta crystallographica. Section E, Crystallographic communications

Published: March 23, 2026

Encorafenib plus binimetinib for BRAF V600-mutated thyroid cancer in Japan: final analysis.

Encorafenib plus binimetinib for BRAF V600-mutated thyroid cancer in Japan: final analysis.

Journal: International journal of clinical oncology

Published: March 12, 2026

Showing 1-12 of 457

Last Updated: 09/26/2026